Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Cholesterol Medicines:Side Effects May Outweigh Benefits

MEDIA RELEASE                                                                         

3 JUNE 2013

Cholesterol-lowering Medicines In Elderly People: Side Effects May Outweigh Benefits

At least four in every ten Australians over the age of 65 are taking a cholesterol-lowering medicine, with statins such as atorvastatin, simvastatin and rosuvastatin the most commonly prescribed. However, according to an article in the June edition of Australian Prescriber, the risk of side effects in frail elderly people may outweigh the benefits of continuing on a statin.

Associate Professor Sarah Hilmer and Dr Danijela Gnjidic of the University of Sydney say that statins lower the chance of a heart attack or death in older people who have already had a heart attack. However, the benefit of statins in older people who do not already have heart disease is less clear.

“Statins can cause side effects, and these are more likely in people aged over 70, especially those taking several other medicines,” write the authors.

“Muscle pain or muscle damage are the most common side effects that cause people to stop treatment. Statins can also cause liver problems,” said the authors.

“Statins have also been found to contribute to memory loss or confusion in some people. This side effect may be reversed when statins are stopped.”

NPS MedicineWise clinical adviser Dr Philippa Binns says that it is important that people who have questions or concerns about their medicines talk to their doctor to get personalised advice.

“The benefits of a medicine must always be balanced against the harms,” says Dr Binns.

“It’s also natural that your priorities and your ability to tolerate a medicine may change over time. What’s important is that you don’t stop taking your medicine without consulting your doctor.”

To read the full article and others visit www.australianprescriber.com

People with questions about their medicine can call the NPS Medicines Line (1300 MEDICINE or 1300 633 424), Monday to Friday 9am to 5pm AEST.

ENDS.

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Interest Rates: RBNZ Hikes OCR To 3.5%, ‘Period Of Assessment’ Now Needed

Reserve Bank governor Graeme Wheeler raised the official cash rate as expected, while signalling a pause in rate hikes to assess the impact of moves so far this year. The kiwi dollar sank after Wheeler said its strength was “unjustified” and that the currency could have “a significant fall.” More>>

ALSO:

Fonterra: Canpac Site 'Resize' To Focus More On Paediatrics

Fonterra is looking at realigning its packing operations at Canpac, in the Waikato, to focus more on paediatric nutritionals... The proposed changes could mean around 110 roles may not be required at the site which currently employs 330. More>>

ALSO:

Scoop Business: Postie Plus Brand Gets 2nd Chance With Well-Funded Pepkor

The Postie Plus brand is getting a new lease of life after South Africa’s Pepkor bought the failed retailer’s assets out of administration and said it will use its purchasing power to reduce costs of stock and fatten margins. More>>

ALSO:

Warming: Warming Signs From State Of Climate Report

Climate data from air, land, sea and ice in 2013 'reflect trends of a warming planet' -- says the latest State of the Climate report, launched by U.S. and New Zealand scientists. More>>

ALSO:

Scoop Business: Embrace Falling Home Affordability, Says NZIER

Despair over the inability to afford a house is misplaced and should be embraced as an opportunity to invest in more wealth-creating activity, says the principal economist at the New Zealand Institute of Economic Research, Shamubeel Eaqub. More>>

Productivity Commission: NZ Regulation Not Keeping Pace

New Zealand regulators often have to work with out-of-date legislation, quality checks are under strain, and regulatory workers need better training and development. More>>

ALSO:

Callaghan Innovation: Investment To Help Deepen Innovation Reporting

Callaghan Innovation, the government’s high tech HQ for Kiwi business, is to help deepen New Zealand media coverage of the commercialisation of innovation through an arms-length partnership with independent business news service BusinessDesk. More>>

ALSO:

Tax Credits, Grants: Greens $1Bn R&D Plan

In the Party’s headline economic announcement, the Greens have launched their plan to build a smarter, more innovative economy which has as its centrepiece an additional $1 billion of government investment in research and development (R&D) above current spend, including tax breaks for business. More>>

ALSO:

Get More From Scoop

 
 
Computer Power Plus

Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news